Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will ...

Details for Auron’s poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B Protein ...

Details for Auron’s poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B ...

Details for Auron's poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B Protein ...